Ancillary OON denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for ancillary oon are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied This Out-of-Network Ancillary Service as Not FDA-Approved

For ancillary services — as opposed to drugs or devices — an "FDA approval" denial typically means that a device, piece of equipment, or procedure used during the service has not received FDA clearance or approval, or that the specific application is outside the FDA-cleared indication. This arises with emerging DME categories, software-based therapeutic devices, certain diagnostic tools, or novel rehabilitation technologies.

This denial is often appealable because FDA clearance standards and clinical appropriateness standards are not identical. A service may have regulatory pathway status (510(k) clearance, Breakthrough Device designation, Humanitarian Device Exemption) that Aetna's reviewer did not account for, or the clinical literature may support use even where FDA labeling is silent.

## Federal Appeal Rights

• Internal appeal: File within 180 days of the denial. Aetna must decide within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719): Denials based on lack of FDA approval for a device or procedure qualify for IRO review. File for external review within approximately 4 months of the final internal denial.
• Expedited review: Available when delay poses a serious risk; 72-hour decision window.
• ERISA §503: Full-and-fair review rights apply; request the specific FDA-status standard Aetna applied.

## Documents to Gather

1. FDA regulatory status documentation — obtain the FDA 510(k) clearance letter, premarket approval document, or other regulatory determination for the device or technology; download directly from the FDA's public 510(k) database or the manufacturer. 2. Intended use and cleared indication — confirm the FDA-cleared indication and how the prescribed use aligns with it; if it is an off-label use, document why clinical evidence supports it. 3. Prescriber medical-necessity letter — a signed statement from the ordering clinician explaining the clinical rationale and referencing applicable specialty society or guideline organization guidance. 4. Peer-reviewed clinical evidence — published literature supporting the use of the device or service in this clinical context. 5. Aetna's Clinical Policy Bulletin — identify which CPB was applied and what FDA standard it requires; check whether the CPB is current with respect to the device's regulatory history. 6. Prior treatment history — documentation that FDA-cleared or standard alternatives were used and were inadequate.

## Criteria-Mapping Structure

For each basis Aetna cited, provide a direct documentary answer: FDA clearance number and date, the cleared indication language, the treating clinician's explanation of how the use fits within or is clinically equivalent to that indication, and any guideline organization statements recognizing the technology.

## Practical Next Step

If the device has recently received FDA clearance or has a pending application, obtain a letter from the manufacturer documenting regulatory status — this is often the single most decisive piece of new evidence in a not-FDA-approved appeal.